

Diaceutics PLC

Issue of Share Options/PDMR Shareholdings

Belfast and London, 29 July 2024- Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, announces the issue of 1,494,051 share options over ordinary shares of £0.002 each in the Company ("**Share Options**") to certain directors, members of the Company's senior management team and other key staff, pursuant to the Company's Employee Share Option Plan ("**ESOP**") on 23 July 2024. These awards are made in accordance with the Company's long term incentive plan as detailed in the Company's Annual Report.

Share Options were granted as to PDMRs follows:

<i>Name</i>	<i>Number of Share Options granted</i>	<i>Total no. of ordinary shares under option post grant</i>	<i>% of existing issued share capital</i>	<i>Effective Grant date</i>
Ryan Keeling, CEO	236,250	581,947	0.69%	23 July 2024
Nick Roberts, CFO	168,750	327,622	0.39%	23 July 2024
Julie Browne, COO and PDMR	76,631	245,678	0.29%	23 July 2024
Jordan Clark, CDO and PDMR	74,502	190,242	0.22%	23 July 2024
Susanne Munksted, CPO and PDMR	74,647	284,829	0.34%	23 July 2024
Jillian Beggs, CCO and PDMR	72,844	129,548	0.15%	23 July 2024

A further 790,927 Share Options were granted to a total of 53 other employees.

The Share Options vest on a sliding scale up to 100%, after three years from the date of grant (the "**Performance Period**"), subject to the satisfaction of certain performance criteria. The performance criteria are based upon the growth during the Performance Period in Total Shareholder Return ("**TSR**"), the revenue Compound Annual Growth Rate ("**CAGR**") and recurring revenue. The average mid-market closing share price in the three days prior to the issue of the Share Options was £1.33. The exercise price of the Share Options is £0.002 per share which equates to the nominal value of the ordinary shares.

Following this grant, the total number of share options outstanding in the Company is 4,711,454 representing approximately 5.56% of its current issued share capital of 84,720,076.

Enquiries:

Diaceutics PLC

Nick Roberts, Chief Financial Officer

Tel: +44 (0)28 9040 6500

investorrelations@diaceutics.com

Stifel Nicolaus Europe Limited (Nomad & Broker)

Ben Maddison
Nick Harland
Kate Hanshaw

Tel: +44 (0)20 7710 7600

Alma Strategic Communications

Caroline Forde,
Kinvara Verdon
Kieran Breheny

Tel: +44(0)20 3405 0205

diaceutics@almastrategic.com

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014						
1 Details of the person discharging managerial responsibilities/person closely associated						
a.	Name	Ryan Keeling				
2 Reason for notification						
a.	Position/Status	Chief Executive Officer				
b.	Initial notification/ Amendment	Initial				
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2p each ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Grant of share options				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Exercise price of 0.2p per share</td> <td>236,250</td> </tr> </tbody> </table>	Price(s)	Volume(s)	Exercise price of 0.2p per share	236,250
Price(s)	Volume(s)					
Exercise price of 0.2p per share	236,250					
e.	Date of the transaction	23 July 2024				
f.	Place of the transaction	Outside a trading venue				

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1 Details of the person discharging managerial responsibilities/person closely associated		
a.	Name	Nick Roberts
2 Reason for notification		

a.	Position/Status	Chief Finance Officer				
b.	Initial notification/ Amendment	Initial				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2p each ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Grant of share options				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Exercise price of 0.2p per share</td> <td>168,750</td> </tr> </tbody> </table>	Price(s)	Volume(s)	Exercise price of 0.2p per share	168,750
Price(s)	Volume(s)					
Exercise price of 0.2p per share	168,750					
e.	Date of the transaction	23 July 2024				
f.	Place of the transaction	Outside a trading venue				

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1	Details of the person discharging managerial responsibilities/person closely associated	
a.	Name	Julie Browne
2	Reason for notification	
a.	Position/Status	Chief Operations Officer
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2p each ISIN: GB00BJQTGV64
b.	Nature of the transaction	Grant of share options
c.	Price(s) and volume(s)	

		<table border="1"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>Exercise price of 0.2p per share</td> <td>76,631</td> </tr> </table>	Price(s)	Volume(s)	Exercise price of 0.2p per share	76,631
Price(s)	Volume(s)					
Exercise price of 0.2p per share	76,631					
e.	Date of the transaction	23 July 2024				
f.	Place of the transaction	Outside a trading venue				

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014						
1 Details of the person discharging managerial responsibilities/person closely associated						
a.	Name	Jordan Clark				
2 Reason for notification						
a.	Position/Status	Chief Data Officer				
b.	Initial notification/ Amendment	Initial				
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2p each ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Grant of share options				
c.	Price(s) and volume(s)	<table border="1"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>Exercise price of 0.2p per share</td> <td>74,502</td> </tr> </table>	Price(s)	Volume(s)	Exercise price of 0.2p per share	74,502
Price(s)	Volume(s)					
Exercise price of 0.2p per share	74,502					
e.	Date of the transaction	23 July 2024				
f.	Place of the transaction	Outside a trading venue				

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1 Details of the person discharging managerial responsibilities/person closely associated		
a.	Name	Susanne Munksted
2 Reason for notification		
a.	Position/Status	Chief Precision Medicine Officer

b.	Initial notification/ Amendment	Initial				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2p each ISIN: GB00BJQTV64				
b.	Nature of the transaction	Grant of share options				
c.	Price(s) and volume(s)	<table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Exercise price of 0.2p per share</td> <td>74,647</td> </tr> </tbody> </table>	Price(s)	Volume(s)	Exercise price of 0.2p per share	74,647
Price(s)	Volume(s)					
Exercise price of 0.2p per share	74,647					
e.	Date of the transaction	23 July 2024				
f.	Place of the transaction	Outside a trading venue				

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014						
1	Details of the person discharging managerial responsibilities/person closely associated					
a.	Name	Jillian Beggs				
2	Reason for notification					
a.	Position/Status	Chief Commercial Officer				
b.	Initial notification/ Amendment	Initial				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2p each ISIN: GB00BJQTV64				
b.	Nature of the transaction	Grant of share options				
c.	Price(s) and volume(s)	<table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)		
Price(s)	Volume(s)					

		Exercise price of 0.2p per share	72,844
e.	Date of the transaction	23 July 2024	
f.	Place of the transaction	Outside a trading venue	

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHBVLLLZDLBBBD